Bio Medica Laboratories IPO Review: Indore Parenteral Injectable Manufacturer Opens 21 May 2026 at Rs 131-139 on NSE SME

The Bio Medica Laboratories IPO opens for subscription on 21 May 2026 on the NSE SME platform with a price band of Rs 131 to Rs 139 per share. The issue is a combination of a fresh issue of 33,94,800 equity shares and an offer for sale (OFS) of 3,76,800 equity shares, for a total issue of 37,71,600 equity shares, raising approximately Rs 52.4 crore at the upper band. Bio Medica Laboratories Limited is an Indore, Madhya Pradesh-based pharmaceutical company established in 2015, engaged in the manufacturing of parenteral formulations including liquid injectables and dry powder injections for human and veterinary healthcare on a B2B contract manufacturing model.

The Bio Medica Laboratories IPO GMP stands at Rs 0 as of 19 May 2026, indicating no grey market premium and an expected listing at or near the Rs 139 issue price. The nil GMP, combined with the relatively small issue size, reflects cautious grey market sentiment ahead of the subscription period opening on 21 May.

Bio Medica Laboratories IPO Key Details

• IPO Open Date: 21 May 2026 (Wednesday)
• IPO Close Date: 23 May 2026 (Friday)
• Allotment Date: 26 May 2026
• Credit of Shares: 27 May 2026
• Listing Date: 29 May 2026 (NSE SME)
• Price Band: Rs 131 to Rs 139 per share
• Issue Structure: Fresh Issue 33,94,800 shares + OFS 3,76,800 shares = 37,71,600 total shares
• Total Issue Size: Approximately Rs 52.4 crore at upper band of Rs 139
• Lot Size: 1,000 shares per lot
• Minimum Retail Application: 2 lots (2,000 shares) at Rs 2,78,000 at upper band
• Minimum HNI Application: 3 lots (3,000 shares) at Rs 4,17,000
• GMP (19 May 2026): Rs 0 (nil — expected listing at or near Rs 139 issue price)
• Registrar: Skyline Financial Services Pvt Ltd
• CEO: Pradeep Mehta
• Listing Exchange: NSE SME

Track Bio Medica Laboratories IPO subscription and live data on the Check the Univest Screener for live data.

About Bio Medica Laboratories: Business and Products

Bio Medica Laboratories Limited was established in 2015 in Indore, Madhya Pradesh, under the leadership of CEO Pradeep Mehta. The company is primarily a B2B contract manufacturer of parenteral pharmaceutical formulations — a specialised and technically demanding segment of the pharmaceutical manufacturing market. Parenteral products are drugs administered by any route other than through the digestive tract, primarily injections, and require sterile manufacturing environments and stringent quality control.

The company manufactures two core product categories: liquid injectables (solutions and suspensions for intravenous, intramuscular and subcutaneous administration) and dry powder injections (lyophilised or powder formulations reconstituted before injection). Products are manufactured for both human healthcare and veterinary healthcare segments. The company supplies ethical drugs, generic medicines and OTC products to pharmaceutical companies across multiple Indian states as a contract manufacturer rather than marketing its own branded products.

• Manufacturing Location: Indore, Madhya Pradesh
• Product Focus: Liquid injectables and dry powder injections for human and veterinary use
• Business Model: B2B contract manufacturing — supplies to pharma companies, not direct to hospitals or patients
• Quality Certifications: GMP (Good Manufacturing Practices) certificate from Food and Drugs Administration, Madhya Pradesh; GLP (Good Laboratory Practices) certified
• Distribution States: Arunachal Pradesh, Chhattisgarh, Gujarat, Haryana, Karnataka, Madhya Pradesh, Tamil Nadu, West Bengal, Telangana, Uttar Pradesh, Rajasthan and others

Bio Medica Laboratories IPO Use of Proceeds

As a combination issue, proceeds are split between fresh issue capital for the company and OFS proceeds for existing shareholders:

• Fresh Issue Proceeds: Available for company use — expected to fund capacity expansion, working capital and general corporate purposes. Full allocation breakdown available in the RHP.
• OFS Proceeds: Go to existing shareholders selling their stake. The 3,76,800 OFS shares represent approximately 10% of the total issue, meaning most proceeds do flow to the company.

Tap to Access Best Research Pieces on Univest

Key Strengths of Bio Medica Laboratories IPO

• Specialised Parenteral Manufacturing: Parenteral injectable manufacturing is one of the most technically complex and regulated segments of the pharmaceutical industry. The high entry barrier creates a competitive moat for established players with GMP certification and sterile manufacturing capabilities.
• GMP + GLP Certified: Dual certification (GMP and GLP) from the Madhya Pradesh FDA indicates the company meets both manufacturing and laboratory quality standards, making it eligible for government and hospital procurement contracts.
• Veterinary Healthcare Exposure: The veterinary injectable market is under-served in India and growing with rising pet ownership and commercial livestock healthcare spending. Bio Medica’s dual human and veterinary focus provides market diversification.
• B2B Model with Wide Geographic Reach: Supplying to pharma companies across 11-plus Indian states provides diversified revenue distribution and reduces dependence on any single client geography.
• India Injectable Market Growth: India’s parenteral drug formulations market is expanding rapidly driven by hospital infrastructure growth, Ayushman Bharat scheme coverage expansion and the shift from oral to injectable therapies in critical care.

Key Risks and Concerns in the Bio Medica Laboratories IPO

• Zero GMP: Rs 0 GMP as of 19 May 2026 is the most significant near-term red flag. No grey market premium means the market has no listing gain expectation at present. Investors should not apply primarily for listing gains.
• Relatively New Incorporation (2015): With only 10 years of operational history and limited public financial disclosure history, Bio Medica has a shorter track record than established parenteral manufacturers like Gland Pharma, Hikma or Claris.
• High Minimum Investment: Rs 2,78,000 minimum retail application (2,000 shares at Rs 139) is a significant capital commitment for a nil-GMP IPO. Capital is blocked for approximately 5 days between application (21 May) and listing (29 May).
• Contract Manufacturing Dependency: Operating as a B2B contract manufacturer means revenue depends on client pharma companies’ production orders. Any slowdown in client order books or client consolidation could reduce demand for Bio Medica’s manufacturing capacity.
• Sterile Manufacturing Regulatory Risk: Parenteral manufacturers face the most stringent CDSCO (Central Drugs Standard Control Organisation) oversight in Indian pharma. Any GMP observations, warning letters or manufacturing deficiencies would directly impact the company’s ability to supply clients.
• OFS Component: The 3,76,800 OFS shares allow existing shareholders to exit partially at IPO. While modest (10% of total issue), investor scrutiny of why promoters are selling at this stage is warranted.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and insightful research pieces on Bio Medica Laboratories IPO subscription tracker and NSE SME IPO calendar!

Bio Medica Laboratories IPO: Should You Apply?

The Bio Medica Laboratories IPO has a genuine business story in parenteral injectable contract manufacturing with GMP and GLP certifications, a growing market and geographic diversification. However, the Rs 0 GMP as of subscription opening is a clear signal that the grey market has no conviction in near-term listing gains. This makes the Bio Medica Laboratories IPO suitable only for investors with a long-term fundamental conviction in the parenteral CDMO market, not for listing-gain seekers.

Investors who are interested should review the detailed RHP financials including revenue growth trajectory, PAT margins, client concentration, capacity utilisation and return ratios before committing Rs 2,78,000 in minimum capital. Consult a SEBI-registered advisor before applying.

Conclusion

The Bio Medica Laboratories IPO opens 21 May 2026 on NSE SME at Rs 131 to Rs 139 for approximately Rs 52.4 crore combining a fresh issue and OFS. The Indore-based parenteral injectable contract manufacturer holds GMP and GLP certifications and supplies ethical, generic and OTC injectable products across 11-plus Indian states. GMP is Rs 0, signalling no near-term listing premium expectation. The specialised parenteral manufacturing business model, dual human and veterinary healthcare exposure and India’s growing injectable drug market provide the long-term investment case. Apply only based on long-term conviction in the business, not for listing gain. Track live subscription data on Univest from 21 May.

Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions.

FAQs on Bio Medica Laboratories IPO

When does the Bio Medica Laboratories IPO open and close?

Ans. The Bio Medica Laboratories IPO opens on 21 May 2026 and closes on 23 May 2026. Allotment is on 26 May, share credit on 27 May and listing on NSE SME is on 29 May 2026.

What is the Bio Medica Laboratories IPO GMP today?

Ans. The Bio Medica Laboratories IPO GMP is Rs 0 (nil) as of 19 May 2026. There is no grey market premium or listing gain expectation from the grey market at this stage. This makes the Bio Medica Laboratories IPO a fundamental buy rather than a listing-gain play.

What does Bio Medica Laboratories do?

Ans. Bio Medica Laboratories Limited is an Indore, Madhya Pradesh-based pharmaceutical company established in 2015. It manufactures parenteral formulations including liquid injectables and dry powder injections for human and veterinary healthcare on a B2B contract manufacturing model. The company holds GMP and GLP certifications and supplies to pharma companies across 11-plus Indian states.

What is the minimum investment for Bio Medica Laboratories IPO?

Ans. The minimum retail application for the Bio Medica Laboratories IPO is 2 lots of 1,000 shares each (2,000 shares total) at the upper band of Rs 139, requiring Rs 2,78,000. HNI investors must apply for a minimum of 3 lots (3,000 shares) at Rs 4,17,000.

Is Bio Medica Laboratories IPO a good investment?

Ans. The Bio Medica Laboratories IPO has a genuine business model in a high-barrier parenteral injectable manufacturing segment. However, the nil GMP, new 2015 incorporation, high minimum investment and contract manufacturing dependency are key risks. Suitable only for long-term investors with conviction in the parenteral CDMO market. Consult a SEBI-registered advisor before applying.